Takeda Oncology
Keri Cavanagh currently serves as the Head of Contracts, Pricing, and Analytics for US Patient Value and Access at Takeda Oncology, a position held since August 2023. Prior to this, Keri held the role of VP, Head of Contracting, Pricing, Forecasting, and Insights for Market Access and Patient Solutions at EMD Serono, Inc. from December 2021 to August 2023, and previously served as Associate Director of Contract Operations within the same company from August 2013 to November 2018. Keri's earlier experience includes a position as Senior Contracts Administrator at Draper Laboratory, where management of approximately $60 million in funded contracts was a key responsibility. Keri holds a Doctor of Law (J.D.) degree from New England Law | Boston and a Bachelor's degree in Health Management and Policy from the University of New Hampshire.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.